May 21 (Reuters) - Biogen and Denali Therapeutics said on Thursday they will discontinue development of their Parkinson's ...
Stocktwits on MSN
BIIB, DNLI stocks edge lower after hours: Parkinson’s drug misses key goals in trial
Despite the miss, the companies said the medicine was generally well tolerated with an acceptable safety profile and ...
High-level results have led the companies to scrap the mid-stage trial, though Denali plans to continue independently running ...
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the ...
US biotech Biogen (Nasdaq: BIIB) and Denali Therapeutics (Nasdaq: DNLI) are discontinuing development of Parkinson’s disease ...
From special pens to earwax evaluations, a plethora of emerging diagnostics could one day be a major boon for people with the ...
BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last ...
In the very earliest stages of Parkinson’s, one of the most common symptoms is REM sleep behaviour disorder, in which the person acts out their dreams during sleep, often through movements or sounds.
A noninvasive treatment called high-intensity focused ultrasound helped relieve the shaking, stiffness and pain that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results